Abstracts tagged "anti-TNF therapy"

Abstract Number: 1319 • 2012 ACR/ARHP Annual Meeting
Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial
Daniel Furst¹, Saeed A. Shaikh², Maria W. Greenwald³, Michael H. Schiff⁴, Barbara Bennett⁵, Owen Davies⁶, Fabienne Staelens⁷, Will Koetse⁸ and Philippe Bertin⁹, ¹David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ²Medicine, McMaster University, St Catharines, ON, Canada, ³Desert Medical Advances, Palm Desert, CA, ⁴Rheumatology Division, University of Colorado, Denver, CO, ⁵BABennett Consulting, LLC, Marietta, GA, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Rtp, NC, ⁹Service De Rhumatologie, Dupuytren Hospital, Limoges, France
Background/Purpose: Certolizumab pegol (CZP) has demonstrated efficacy in patients (pts) with prior TNF inhibitor exposure.1 In the Doseflex trial two maintenance dosing regimens of CZP…
Abstract Number: 558 • 2012 ACR/ARHP Annual Meeting
Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study
Joachim Sieper¹, Alan J. Kivitz², A.M. Van Tubergen³, Atul A. Deodhar⁴, Geoffroy Coteur⁵, Franz Woltering⁶ and Robert B. M. Landewé⁷, ¹Medical Department I, Rheumatology, Charité University Medicine, Berlin, Germany, ²Altoona Center for Clinical Research, Duncansville, PA, ³Department of Medicine, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is a form of spondyloarthritis (SpA) that includes both ankylosing spondylitis (AS) and non-radiographic axial SpA (nr-axSpA), as defined by the…
Abstract Number: 363 • 2012 ACR/ARHP Annual Meeting
Risk Factors for Radiographic Progression During TNF-Inhibitor Treatment in 932 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard¹, Pernille Bøyesen², Anja Thormann¹, Ulrik Tarp¹, Wolfgang Bøhme¹, Ditte Dencker¹, Hanne M. Lindegaard³, Uta Engling Poulsen¹, Annette Hansen⁴, Vibeke Stevenius Ringsdal¹, Annette Schlemmer⁵, Niels Graudal¹, Anne Rødgaard Andersen¹, Jakob Espesen¹, Gina Kollerup¹, Torben Grube Christensen¹, Randi Pelck¹, Bente Glintborg¹, Ole Rintek Madsen¹, Dorte Vendelbo Jensen¹, Ole Majgaard¹ and Merete L. Hetland⁶, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ²Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ³Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁴Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: : Despite treatment with tumour necrosis factor inhibitors (TNFi) some rheumatoid arthritis (RA) patients progress radiographically in randomised controlled trials and observational cohorts (1).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].